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Abstract
Emerging data seem to be available also on the role of active throm-
boprophylaxis with heparin and pregnancy outcome. In the last de-
cades we found many data concerning the association between a 
hypercoagulable state and its causes and adverse pregnancy out-
come, in particular recurrent pregnancy loss (RPL). First studies 
which focused on the association between thrombophilia and RPL 
underlined the role of reduced clotting inhibitors and RPL, and 
subsequent studies underlined a pathogenetic role of gene variant 
associated to hypercoagulable state in the occurrence of RPL. On 
the other hand, acquired thrombophilic abnormalities as antiphi-
psholipid syndrome are a well known cause of RPL and should be 
considered for a screening. These data are relevant because recent 
studies suggested a role of an extensive thromprophilaxis in women 
with RPL that should be addressed only in case of known thrombo-
philia and high risk of venous thromboembolism.
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Recurrent pregnancy loss (RPL) represents a major health 
problem with two to three or more losses in up to 5% of 
women of reproductive age and is actually one of the most 
common causes of female sterility [1]. Several reports iden-
tify inherited predisposition to thrombophilia as one of the 
main causes of RPL in particular if several diseases poten-
tially responsible of RPL have been already excluded such 
as endocrine diseases (such as ovarian dysfunction, anovu-
lation, hypopituitarism and diabetes), uterine malformation, 
genetic alterations (for example, chromosomal aberrations), 
inflammatory diseases (in particular systemic lupus erythe-
matosus) and infectious diseases [2-5]. From a pathological 
point of view, women affected by thrombophilia show dur-
ing their pregnancy a hypercoagulable state that is already 
increased  during  pregnancy,  which  may  impair  placental 
flow and then its function and fetal growth and may predis-
pose to develop venous thrombosis [6].
During pregnancy, in fact, we may observe many chang-
es in the haemostatic balance with a trend toward thrombo-
philia in order to be prompt for the haemostatic challenge of 
delivery [2, 6-7]. Thus, pregnancy is a condition associated 
to thrombophilia per se and for this reason it is associated 
with the increase of several clotting factors (namely factor 
VIII, vWF, fibrinogen and factor VII) [7]. Moreover, also 
other markers of a hypercoagulable state are increased dur-
ing pregnancy, such as D-dimer and/or prothrombin frag-
ment 1+2 [7, 8]. For this reason we may observe episodes 
of venous thromboembolism (VTE) during pregnancy [9]. 
Moreover, women carrying further thrombotic risk factors 
such  as  inherited  thrombophilia  show  an  additionally  in-
creased risk of thrombotic events during pregnancy such as 
venous thromboembolism and/or abortion [10].
VTE and pulmonary embolism (PE), in fact, continue 
to be a leading cause of maternal death during pregnancy or 
postpartum and may cause significant morbidity of pregnant 
women. 
The aim of the review is to focus fundamental clinical 
aspect of thrombophilias in the occurrence of RPL.
 
Inherited Thrombophilia and Pregnancy  Loss
Thrombophilia has been identified as one of the main causes 
of RPL with a percentage of until 40%, in particular early 
RPL [11]. Although several studies on this topic are available 
Manuscript accepted for publication February 5, 2010
aDepartment of Obstetrics and Gynecology and Human Reproduction, 
  ‘Federico II’ University of Naples, Naples, Italy
bInternal Medicine Division, Buonconsiglio Fatebenefratelli Hospital 
  of Naples, Naples, Italy
cCorresponding author: Internal Medicine Division, Buonconsiglio 
  Fatebenefratelli Hospital of Naples, Via San Giacomo dei Capri 69,   
  Naples, Italy. Email: pdimicco@libero.it 
doi:10.4021/jocmr2010.02.260w 
 18                                                                                                                                                   19J Clin Med Res  •  2010;2(1):18-22    D’Uva et al
Articles © The authors, Journal compilation © J Clin Med Res and Elmer Press™, www.jocmr.org
in the literature to confirm this trend, rates of thrombophilia 
seem to differ from study to study because of different inclu-
sion criteria and different ethnic backgrounds of the selected 
patients [12]. In this clinical setting we may differentiate 
inherited thrombophilia, acquired thrombophilia and com-
bined thrombophilia [13-14].
Inherited  thrombophilia  may  be  due  to  deficiency  of 
clotting inhibitors or to gene variants leading to a hyperco-
agulable tendency. Gene variants frequently associated with 
RPL are prothrombin A20210G and/or factor V Leiden. Pro-
thrombin A20210G has been identified as a risk factor for 
pregnancy loss in several studies and has been associated 
mainly to early RPL [15-19]. On the other hand, factor V 
Leiden, which is responsible for more than 75% of inherited 
activated protein C resistance, is the more common inherited 
thrombotic risk factor associated to RPL [20-22]. In particu-
lar, a case control study by Ridker et al. has reported an in-
creased prevalence of FVL in women with RPL, while other 
studies revealed a strong relationship between FVL and early 
RPL [23]. FVL has been identified as a risk factor also for 
late RPL [24]. Also deficiency of clotting inhibitors, such as 
protein S, protein C and/or antithrombin, has been clearly 
associated to RPL since 1996 [25, 26].
In the latest years an emerging role has been suggested 
and underlined also for the PAI-1 4G\5G gene variant that 
may be associated to hypofibrinolysis and so to hypercogula-
ble state. Several reports underlined the association between 
4G\4G genotype of PAI-1 and RPL [27, 28] and this associa-
tion seems to be relevant if anamnestic VTE is also present 
[29]. Yet more detailed data on large based population are 
needed in next years.
Hyperhomocysteinemia
A pathogenetic role of hyperhomocysteinemia (HHCY) in 
RPL has been underlined by several reports on this topic, but 
data available in the literature are actually not univocal. Sev-
eral authors reported increasing evidences for the relation-
ship  between  HHCY,  methylenetetrahydrofolate  reductase 
gene polymorphism C677T (MTHFR C677T) and RPL, in 
particular early RPL [25,30-32]. On the other hand, further 
authors found a negative association between HHCY and 
early RPL [33-35].
Acquired Thrombophilia
Several authors underlined the role of the antiphospholipid 
syndrome (APS) in the pathophysiology of RPL [36-48]. To 
confirm this point, actually adverse pregnancy outcome is 
considered as one of the diagnostic criteria of APS (Table 
1) according to the guidelines of the International Society of 
Thrombosis and Haemostasis and the American Rheumatol-
ogy Association [49, 50]. During APS, a large variety of au-
toantibodies also toward clotting factors, such as factor XII, 
has been found [51, 52]. However, a clear explanation of all 
involved processes on the roles of antiphospholipid antibod-
ies and of autoantibodies toward clotting factors is still mat-
ter of discussion. 
On the other hand, new evidence seems to be available 
for the role of increased maternal plasma levels of clotting 
factor VIII and the risk of RPL [53]. Furthermore, acquired 
activated protein C resistance, which is not associated with 
Table 1. Diagnostic Criteria to Detect Antiphospholipid Syndrome
For more details we suggest to consult Miyakis S, et al. J Thromb Haemost. 2006;4:295-306 [50].
Clinical Criteria
(Vascular thrombosis of arterial and/or venous vessels 
in any tissue or organ) 
Pregnancy morbidity
Laboratory Criteria
One or more unexplained deaths of a morphologically 
normal fetus at or beyond the 10th week of gestation
Lupus anticoagulant present in plasma, on two or 
more occasions at least 12 weeks apart, detected 
according to the International Society of Thrombosis 
and Haemostasis (ISTH)
One or more unexplained deaths of a morphologically 
normal neonate before the 34th week of gestation 
because of eclampsia or severe eclampsia or placental 
insufficiency
Anticardiolipin antibody (aCL) of IgG and/or IgM 
isotype in serum or in plasma present in medium or 
high titer on two or more occasions at least 12 weeks 
apart
Three or more unexplained consecutive spontaneous 
abortions before the 10th week of gestation
Anti-β2 glycoprotein-I antibody of IgG and/or IgM 
isotype in serum or in plasma present on two or more 
occasion at least 12 weeks apart
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the presence of FVL, has been described in several women 




Combined  thrombophilia,  namely  inherited  thrombophilia 
associated with acquired thrombophilia or more than one 
inherited thrombophilic defect, has also been identified as 
a cause of RPL, but its real frequency is not clear. Several 
studies in the latest years identified combined thrombophilic 
defects in women with RPL both early RPL and late RPL 
[10, 28, 55]. 
Conclusions
Active surveillance of women referred to gynecological cen-
ters for RPL should be supported by thrombophilia screen-
ing. This approach may be helpful to fight this major health 
problem that involves up to 5% of women of reproductive 
age by an appropriate antithrombotic treatment. Inherited 
and/or acquired thrombophilia has been diagnosed in 50% 
to 65% of women with history of unexplained RPL and in 
nearly 20% of women with RPL with age of more than 35 
years [56].
This gynecological and clinical aspect may be consid-
ered in particular if anamnesis reveals the presence of per-
sonal and\or familial trend to develop thrombotic disorders 
in particular VTE. So an appropriate clinical evaluation fo-
cused on diagnosis and therapy of RPL should also consider 
thrombophilic defects. 
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